Product Images Terbinafine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Terbinafine NDC 70518-4421 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

This is a description of Terbinafine tablets, each containing 250 mg, with a quantity of 90 tablets. The tablets are white and round. The usual dosage is mentioned in the insert. The tablets are repackaged by RemedyRepack Inc. in Indiana, PA. The original NDC number is 69097-0859-07, and the tablets are manufactured by Cipla Ltd in India. It is advised to keep the medication away from children and store it at a temperature range of 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F) as per USP standards.*

MM2 - Terbinafine 250mg 70518 4421 01

MM2 - Terbinafine 250mg 70518 4421 01

Description: Terbinafine Tablets, 250 mg, quantity of 45 tablets. The tablets are round and white. The package is repackaged by RemedyRepack Inc. with NDC number 70518-4421-01. The tablets are manufactured by Cipla Ltd in Kurkumnbh, India. The usual dosage information can be found in the insert included. It is important to store the medication at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). Remember to keep the medication out of the reach of children.*

Image 2 - terbinafine str

Image 2 - terbinafine str

Image 1 - terbinafine table

Image 1 - terbinafine table

This is a table displaying adverse events and discontinuation rates for patients taking Terbinafine Tablets compared to Placebo. Adverse events such as headache, gastrointestinal symptoms (e.g., diarrhea, dyspepsia, abdominal pain, nausea, flatulence), dermatological symptoms (e.g., rash, pruritus, urticaria), liver enzyme abnormalities, taste disturbance, and visual disturbance are listed along with the percentages of patients experiencing them in each group.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.